ArticleDiagnostic pathology2026
Integrating histopathology and immune marker analysis for machine learning-based colorectal cancer prognostics.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to create a machine-learning framework that integrates histopathological imaging, immune marker data, and clinical features to classify tumor types, determine histological grades, and predict survival outcomes in CRC patients. MATERIALS AND
methodsThis study analyzed 650 CRC cases, divided into training (520 cases) and testing (130 cases) subsets. Preprocessing involved quality control, color normalization, and selecting tumor regions (tumor center and invasive margins) with uniform dimensions (224 × 224 pixels). Six immune markers (CD3, CD8, CD45RO, PD-1, LAG-3, Tim-3) were selected for their relevance to CRC progression and immune response. A fine-tuned EfficientNet model was used to extract high-dimensional features from the images. These imaging features were combined with clinical data. To refine the dataset, feature selection methods such as PCA, RFE, and LASSO were applied to include only the most relevant variables. Machine learning models (XGBoost, CatBoost, Random Forest) and ensemble models were developed for tumor type and grade prediction. For survival prediction, regression models such as SVR, Random Forest Regressor, and stacking regressors were used. Model performance was evaluated using metrics such as accuracy, AUC, MSE, and the C-index.
resultsThe evaluation highlighted the value of feature selection and ensemble learning in CRC classification and survival prediction. For tumor type classification, XGBoost with RFE achieved a testing AUC of 86.15% and accuracy of 85.33%, while stacking-based models with RFE performed better, with a testing AUC of 96.73% and accuracy of 96.92%. Histological grade classification followed a similar trend, with stacking-based models achieving a testing AUC of 96.37% and accuracy of 96.92%. In survival prediction, the Stacking Regressor with RFE produced the best results, with testing MSEs of 132.87 for Disease-Free Survival (days) and 115.78 for Survival (days), along with the highest C-index of 0.84 for both tasks.
conclusionsThe proposed framework demonstrates the potential of integrating histopathological imaging, immune markers, and machine learning to improve CRC prognosis and enable personalized treatment, setting a benchmark for future computational pathology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.